207 results on '"Granetto C"'
Search Results
52. KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
53. Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.)
54. Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases
55. Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis
56. Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
57. Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis
58. Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
59. LBA21 - FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
60. 572P - Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer
61. D21 - Tumor-infiltrating lymphocytes (tils) density as prognostic determinant in stage ii colorectal cancer
62. C29 - Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
63. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study
64. The role of comprehensive geriatric evaluation (CGE) in the management of older cancer patients
65. 2* - FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses
66. A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO)
67. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
68. 6085 FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
69. 6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
70. Survival prediction and frequency of anticancer treatment (ACT) near the end of life in patients hospitalized due to acute conditions (AC)
71. A phase II study of neoadjuvant antiangiogenic therapy combined with capecitabine (C) and radiotherapy (RT) in patients (pts) with locally advanced rectal cancer (LARC)
72. Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
73. Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts)
74. 3022 POSTER Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
75. Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
76. A multi-gene algorithm as predictor of response to chemo-radiotherapy in head and neck cancer
77. AlteRCC phase I-II trial: Alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (HNC)
78. Locoregional chemotherapy with pegylated liposomal doxorubicin (PLD) in patients with hepatic malignancies
79. 518P - Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis
80. O-0007 - Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
81. A LOADING DOSE OF TAMOXIFEN FOLLOWED BY A STANDARD DOSE EST FRAIL OLDER WOMEN WITH BREAST CANCER IS FEASIBLE AND EFFECTIVE
82. Lung cancer
83. Prostate cancer
84. Screening and chemoprevention
85. Gynaecologic cancers
86. Paclitaxel plus Ifosfamide in Advanced Ovarian Cancer
87. p53 accumulates in micronuclei after treatment with a DNA breaking chemical, methylnitrosourea, and with the spindle poison, vinblastine
88. 511 Paclitaxel±ifosfamide in advanced ovarian cancer (A.O.C.). Preliminary results of a multicentric pilot study
89. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
90. Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score.
91. Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial
92. Paclitaxel +/- ifosfamide in advanced ovarian cancer (AOC). Preliminary results of a multicentric pilot study
93. Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC)
94. Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
95. Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy
96. Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by Gruppo Oncologico Nord-Ovest (G.O.N.O.)
97. FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis
98. Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the star (Studio terapia adiuvante retto)-01 randomized phase III trial
99. KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
100. Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.